413 related articles for article (PubMed ID: 17728214)
1. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters.
Hoskins JM; Goldberg RM; Qu P; Ibrahim JG; McLeod HL
J Natl Cancer Inst; 2007 Sep; 99(17):1290-5. PubMed ID: 17728214
[TBL] [Abstract][Full Text] [Related]
2. UGT1A1*6 polymorphisms are correlated with irinotecan-induced neutropenia: a systematic review and meta-analysis.
Zhang X; Yin JF; Zhang J; Kong SJ; Zhang HY; Chen XM
Cancer Chemother Pharmacol; 2017 Jul; 80(1):135-149. PubMed ID: 28585035
[TBL] [Abstract][Full Text] [Related]
3. Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea: a meta-analysis.
Hu ZY; Yu Q; Zhao YS
Eur J Cancer; 2010 Jul; 46(10):1856-65. PubMed ID: 20335017
[TBL] [Abstract][Full Text] [Related]
4. Dose-dependent association between UGT1A1*28 genotype and irinotecan-induced neutropenia: low doses also increase risk.
Hu ZY; Yu Q; Pei Q; Guo C
Clin Cancer Res; 2010 Aug; 16(15):3832-42. PubMed ID: 20562211
[TBL] [Abstract][Full Text] [Related]
5. The UGT1A1*28 genotype and the toxicity of low-dose irinotecan in patients with advanced lung cancer.
Sugiyama T; Hirose T; Kusumoto S; Shirai T; Yamaoka T; Okuda K; Ohnishi T; Ohmori T; Adachi M
Oncol Res; 2010; 18(7):337-42. PubMed ID: 20377135
[TBL] [Abstract][Full Text] [Related]
6. UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan.
Stewart CF; Panetta JC; O'Shaughnessy MA; Throm SL; Fraga CH; Owens T; Liu T; Billups C; Rodriguez-Galindo C; Gajjar A; Furman WL; McGregor LM
J Clin Oncol; 2007 Jun; 25(18):2594-600. PubMed ID: 17577039
[TBL] [Abstract][Full Text] [Related]
7. Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms.
Satoh T; Ura T; Yamada Y; Yamazaki K; Tsujinaka T; Munakata M; Nishina T; Okamura S; Esaki T; Sasaki Y; Koizumi W; Kakeji Y; Ishizuka N; Hyodo I; Sakata Y
Cancer Sci; 2011 Oct; 102(10):1868-73. PubMed ID: 21740478
[TBL] [Abstract][Full Text] [Related]
8. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.
Ando Y; Saka H; Ando M; Sawa T; Muro K; Ueoka H; Yokoyama A; Saitoh S; Shimokata K; Hasegawa Y
Cancer Res; 2000 Dec; 60(24):6921-6. PubMed ID: 11156391
[TBL] [Abstract][Full Text] [Related]
9. [Relationship between UGT1A1 gene polymorphisms and irinotecan-induced severe adverse events].
Wang XF; Ma C; Gong FF; Yi SY; Xing GC; Wang KJ; Yang Q; Cao W
Zhonghua Zhong Liu Za Zhi; 2018 Aug; 40(8):594-599. PubMed ID: 30139029
[No Abstract] [Full Text] [Related]
10. Clinical observations on associations between the UGT1A1 genotype and severe toxicity of irinotecan.
Lu YY; Huang XE; Wu XY; Cao J; Liu J; Wang L; Xiang J
Asian Pac J Cancer Prev; 2014; 15(7):3335-41. PubMed ID: 24815493
[TBL] [Abstract][Full Text] [Related]
11. Re: UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters.
Ichikawa W; Araki K; Fujita K; Yamamoto W; Endo H; Nagashima F; Tanaka R; Miya T; Kodama K; Sunakawa Y; Narabayashi M; Ando Y; Akiyama Y; Kawara K; Sasaki Y
J Natl Cancer Inst; 2008 Feb; 100(3):224-5; author reply 225. PubMed ID: 18230796
[No Abstract] [Full Text] [Related]
12. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma.
Liu CY; Chen PM; Chiou TJ; Liu JH; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Wang WS
Cancer; 2008 May; 112(9):1932-40. PubMed ID: 18300238
[TBL] [Abstract][Full Text] [Related]
13. [UGT1A1 Genotyping for Proper Use of Irinotecan].
Matsuoka A; Ando Y
Rinsho Byori; 2015 Jul; 63(7):876-82. PubMed ID: 26591441
[TBL] [Abstract][Full Text] [Related]
14. Impact of the UGT1A1*28 allele on response to irinotecan: a systematic review and meta-analysis.
Dias MM; McKinnon RA; Sorich MJ
Pharmacogenomics; 2012 Jun; 13(8):889-99. PubMed ID: 22676194
[TBL] [Abstract][Full Text] [Related]
15. UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicity.
Biason P; Masier S; Toffoli G
J Chemother; 2008 Apr; 20(2):158-65. PubMed ID: 18467239
[TBL] [Abstract][Full Text] [Related]
16. Increased frequency of uridine diphosphate glucuronosyltransferase 1A1 7/7 in patients experiencing severe irinotecan-induced toxicities.
Fakih MG; Ross ME; Starostik P
Clin Colorectal Cancer; 2007 Jul; 6(8):583-7. PubMed ID: 17681105
[TBL] [Abstract][Full Text] [Related]
17. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.
Innocenti F; Undevia SD; Iyer L; Chen PX; Das S; Kocherginsky M; Karrison T; Janisch L; RamÃrez J; Rudin CM; Vokes EE; Ratain MJ
J Clin Oncol; 2004 Apr; 22(8):1382-8. PubMed ID: 15007088
[TBL] [Abstract][Full Text] [Related]
18. UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients.
Onoue M; Terada T; Kobayashi M; Katsura T; Matsumoto S; Yanagihara K; Nishimura T; Kanai M; Teramukai S; Shimizu A; Fukushima M; Inui K
Int J Clin Oncol; 2009 Apr; 14(2):136-42. PubMed ID: 19390945
[TBL] [Abstract][Full Text] [Related]
19. Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.
Soepenberg O; Dumez H; Verweij J; de Jong FA; de Jonge MJ; Thomas J; Eskens FA; van Schaik RH; Selleslach J; Ter Steeg J; Lefebvre P; Assadourian S; Sanderink GJ; Sparreboom A; van Oosterom AT
Clin Cancer Res; 2005 Feb; 11(4):1504-11. PubMed ID: 15746053
[TBL] [Abstract][Full Text] [Related]
20. UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan.
Ferraldeschi R; Minchell LJ; Roberts SA; Tobi S; Hadfield KD; Blackhall FH; Mullamitha S; Wilson G; Valle J; Saunders M; Newman WG
Pharmacogenomics; 2009 May; 10(5):733-9. PubMed ID: 19450125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]